Literature DB >> 6822360

The morbidity and utility of periaortic radiotherapy in cervical carcinoma.

R Potish, L Adcock, T Jones, S Levitt, K Prem, J Savage, L Twiggs.   

Abstract

From 1971 through 1981, 81 women received 4350 to 5075 rad to the periaortic lymph nodes as part of their primary management for carcinoma of the uterine cervix. While two patients developed chronic small bowel damage, only one required surgical intervention. Five-year disease-free survival was 40%. Approximately one-third of the first recurrences were within the pelvic and periaortic radiation portals, with the remainder in the lungs, liver, bones, abdomen, and supraclavicular lymph nodes. Radiation dose and volume guidelines are presented in order to minimize enteric morbidity.

Entities:  

Mesh:

Year:  1983        PMID: 6822360     DOI: 10.1016/0090-8258(83)90110-5

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  3 in total

1.  Chemoradiotherapy: the new standard care for invasive cervical cancer.

Authors:  P G Rose
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

2.  3D radiation therapy or intensity-modulated radiotherapy for recurrent and metastatic cervical cancer: the Shanghai Cancer Hospital experience.

Authors:  Su-Ping Liu; Xiao Huang; Gui-Hao Ke; Xiao-Wei Huang
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

3.  Prognostic factors associated with radiotherapy for cervical cancer with computed tomography-detected para-aortic lymph node metastasis.

Authors:  Szu-Yuan Wu; Eng-Yen Huang; Chan-Chao Chanchien; Hao Lin; Chong-Jong Wang; Li-Min Sun; Hui-Chun Chen; Fu-Min Fang; Hsuan-Chih Hsu; Yu-Jie Huang
Journal:  J Radiat Res       Date:  2013-06-27       Impact factor: 2.724

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.